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Abstract
Background: Medication for attention deficit hyperactivity disorder (ADHD) should be closely monitored to ensure
optimisation. There is growing interest in using computerised assessments of ADHD symptoms to support
medication monitoring. The aim of this study was to assess the feasibility and acceptability of a randomised
controlled trial (RCT) to evaluate the efficacy of one such computerised assessment, the Quantified Behavior (Qb)
Test, as part of medication management for ADHD.
Methods: This feasibility multi-site RCT conducted in child and adolescent mental health and community paediatric
settings recruited participants aged 6–15 years diagnosed with ADHD starting stimulant medication. Participants were
randomised into one of two arms: experimental (QbTest protocol) where participants completed a QbTest at baseline
and two follow-up QbTests on medication (2–4 weeks and 8–10 weeks later) and control where participants received
treatment as usual, including at least two follow-up consultations. Measures of parent, teacher, and clinician-rated
symptoms and global functioning were completed at each time point. Clinicians recorded treatment decision-making
and health economic measures were obtained. Data were analysed using multi-level modelling and participants
(children and parents) and clinicians were interviewed about their experiences, resulting data were thematically analysed.
Results: Forty-four children and young people were randomised. Completion of study outcome measures by care-givers
and teachers ranged from 52 to 78% at baseline to 47–65% at follow-up. Participants reported the questionnaires to be
useful to complete. SNAP-IV inattention scores showed greater reduction in the intervention than the control group
(− 5.85, 95% CI − 10.33, − 1.36,). Engagement with the intervention ranged from 100% at baseline, to 78%
follow-up 1 and 57% follow-up 2. However, only 37% of QbTests were conducted in the correct time period. Interview
data highlighted that the objectivity of the QbTest was appreciated by clinicians and parents. Clinicians commented
that the additional time and resources required meant that it is not feasible to use QbTest for all cases.
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Conclusion: The trial design and protocol appear to be feasible and acceptable but could be improved by modifying
QbTest time periods and the method of data collection. With these changes, the protocol may be appropriate for a full
trial. Adding QbTest may improve symptom outcome as measured by SNAP-IV.
Trial registration: ClinicalTrials.gov, NCT03368573, prospectively registered, 11th December 2017, and ISRCTN, ISRCTN6
9461593, retrospectively registered, 10th April 2018
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Key messages regarding feasibility
1. What uncertainties existed regarding feasibility?
The uncertainties that existed regarding feasibility sur-
rounded the following:
 Whether clinical settings could schedule the
additional repeated QbTests and clinical
appointments as per the intervention protocol.
2. What are the key feasibility findings?
The key feasibility findings are the following:
 It was difficult for clinics to integrate the additional
QbTests and clinical appointments into their
current clinical pathway.
 Care-givers were accepting of the protocol and were
supportive of attending additional appointments.
 Clinicians viewed the repeated QbTests as positive
and beneficial, but wanted to retain autonomy to
decide which patients they should offer follow-up
QbTests to and how frequently these follow-ups
should be conducted, in a future protocol rather
than a ‘one size fits all’ approach.
 Time taken between diagnosis and first QbTest to
uptake of medication took longer than anticipated
which slowed recruitment.
3. What are the implications of the feasibility findings
for the design of the main study?
The implications of the feasibility findings surround
the need for a more flexible intervention protocol that
can work with the varying demand and timescales for
scheduling repeated QbTests at clinics, as well as enable
clinicians to retain autonomy for which patients would
be best supported by additional QbTests to monitor
medication outcomes rather than a blanket approach.
Background
Attention deficit/hyperactivity disorder (ADHD) is a
neurodevelopmental disorder, with core symptoms of
hyperactivity, inattention, and impulsivity. ADHD affects
around 3–5% of children and young people under 18
years old in the UK [1], impacts health-related quality of
life [2], impairs academic and social function, and in-
creases risk of substance misuse, unemployment, and
mental health problems [3–5]. Furthermore, parenting a
child with ADHD can place additional psychological and
financial burden on families [6, 7]. Thus, it is essential
that children have timely access to evidence-based treat-
ments to reduce symptoms and impairment, support
family functioning, and reduce burden on social and
healthcare systems [8].
NICE ADHD guidelines [1] recommend children aged
over 5 years should be started on methylphenidate as a
first-line choice, with treatment tailored to the needs of
the individual through frequent monitoring to balance
optimal symptom reduction with minimal side effects
during titration. Similar recommendations are made by
the American Academic of Pediatrics [9], Canadian
ADHD Practice Guidelines [10], and the European ADHD
Guidelines Group (https://adhd-institute.com/) [11]. A
systematic review and network analysis of 133 RCTs
found that medications for ADHD, including methylphen-
idate and amphetamines, are superior to placebo, demon-
strating their efficacy in treating the symptoms of ADHD
in children and young people [12]. This review also
reported that tolerability (measured as study drop-outs
due to adverse events) was worse than placebo only for
amphetamines and guanfacine in children, suggesting that
most ADHD medications are well-tolerated. There is also
compelling evidence, however, that the efficacy of ADHD
medications and the number of side effects reported are
dependent on the child receiving an optimal dose [13] and
that carefully monitored dose titration is associated with
better clinical outcomes [14]. Audit data from NHS Trusts
within the UK indicate that regular monitoring during
titration often does not occur [15] and many families are
dissatisfied with the service [15, 16]. As a result of time
delay to receiving optimal treatment, children may not be
fully benefiting from medication, which may impact on
their continuing social, societal and academic perform-
ance, as well as increase their risk of medication non-
adherence. Indeed, 50% of patients have stopped ADHD
medication after 18months and 80% after 3 years [17].
Williams et al. Pilot and Feasibility Studies            (2021) 7:68 Page 2 of 18
Current practice to evaluate medication effectiveness
relies on the clinician integrating the opinions of
parents, teachers, the young person, and their own ob-
servations, which are often supported by rating scales.
Delays in receiving these various sources of information,
as well as the subjective and often contradictory nature
of the reports, can lead to delays in treatment decisions.
To help overcome these difficulties, some UK healthcare
clinics have recently incorporated a commercial, object-
ive computerised test of attention, impulsivity, and activ-
ity called ‘QbTest’ (Qbtech Ltd, www.qbtech.com), to
support clinical decision-making. The test is approved
by the FDA (ref: K133382) to be integrated into standard
care to support clinical decision-making for diagnosis or
medication for ADHD but should not be used as a
‘stand-alone’ test. Briefly, the test combines a compu-
terised test of attention and impulsivity, with an infrared
motion capture of head movement to measure activity
during the task. The QbTest requires the patient to re-
spond to an infrequently presented stimulus (by pressing
a button) but ignore all other stimuli. QbTest provides
information on each of the three symptom domains of
ADHD (hyperactivity, inattention, and impulsivity) and
provides a summary report based on deviation from a
normative age and gender data set [18]. Further details
on the QbTest have been published [19, 20].
Research has identified the potential utility of the
QbTest as a clinical tool to aid ADHD assessment and
management [21]. The test has been shown to aid in the
differentiation of ADHD from other conditions [22–24],
increase clinician confidence in diagnostic decision-making
[20], reduce the number of appointments to make a diag-
nosis [20], and result in cost-savings to health services [25].
Although comparatively less researched than its use for
diagnosis, qualitative findings from a recent randomised
controlled trial (RCT) indicate the potential for QbTest to
aid medication management [26, 27]. Clinician interviews
have identified that the QbTest is useful in supporting their
confidence in starting medication, choosing suitable titra-
tion schedules, communicating to families/schools about
medication efficacy, and promoting medication adherence
[26]. As well as being valued by clinicians, QbTest has been
shown to be efficacious as a tool to assess symptom change
as a result of medication. For example, evidence shows the
QbTest is sensitive to detecting changes in ADHD symp-
toms arising from stimulant medication in boys [28], and
one study in adults shows that QbTest was more sensitive
to medication effects than a standardised rating scale [29].
Another study has shown it may be useful in identifying
partial or non-responders after a single dose [30].
Despite growing recognition of the value of QbTest in
ADHD assessment and monitoring, there is a lack of evi-
dence as to whether the QbTest should be incorporated
into routine practice, whether this would be feasible to
do so, and whether this approach would result in im-
proved outcomes. The aim of the QbTest Utility for
Optimising Treatment in ADHD’ (QUOTA) study was
to develop a medication management protocol for the
incorporation of QbTest [19] and test the feasibility and
acceptability of the protocol in a feasibility RCT. The
findings of the trial will be used to determine whether a
future definitive RCT, to test the impact of a QbTest




The study was a parallel group, single-blind, feasibility RCT
with embedded qualitative evaluation. The study was
conducted across five child and adolescent mental health
services (CAMHS) or community paediatric clinics in the
Midlands and South of England, between December 2017
and October 2018. The protocol, including choice of out-
come measures and timing of the interventions were co-
designed by patient and public involvement (PPI) members,
clinicians, and academics. Full details of the study protocol
and the development of its design have been published [19,
31]. The trial was prospectively registered with ISRCTN,
trial registration number ISRCTN69461593 and Clinical
Trials registration number NCT03368573, and conducted
according to CONSORT (Consolidated Standards of
Reporting Trials [32]) guidelines for feasibility studies (flow
diagram (Fig. 1) and checklist (Additional file 1)).
Since the publication of the initial protocol [19], there
has been one change to the trial to extend the recruitment
period from July 2018 to October 2018 and increase the
number of participating research sites from three to five.
These two changes were made in response to lower
numbers of eligible participants in the ADHD pathway at
the initial sites.
Participants
Eligible patients were aged 6–17 years, with a clinical
diagnosis of ADHD, and about to commence stimulant
medication (i.e. methylphenidate or lisdexamfetamine).
Exclusion criteria were non-fluent English, unable to
provide written consent, or a suspected severe learning
disability. No changes to the eligibility criteria were
made during the trial. Potential participants were identi-
fied, recruited, and consented by either clinicians or
clinical research staff at the sites. In line with recom-
mendations for feasibility sample sizes, we aimed to
recruit 60 participants (30 per study arm) to test the
feasibility and establish preliminary efficacy [33]. All
participants were invited to take part in qualitative inter-
views (see Fig. 1 for participant flow).
The study received ethical approval from the West of
Scotland Research Ethics Committee on 7th November
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2017, REC ref: 17/WS/0209, and permission was sought
from and granted by each National Health Service
(NHS) Trust involved in the trial. Written informed con-
sent was obtained—for children aged under 16, written
consent was obtained from the parent/legal guardian
and verbal or written assent was obtained from the
child/young person.
Interventions
Experimental arm (QbTest medication monitoring)
The QbTest medication monitoring intervention added
QbTest to treatment as usual (TAU). QbTests were
completed at baseline, and then 2 to 4 weeks later. At
each time point, the clinician reviewed QbTest results
along with other clinical tools to monitor medication
(follow-up 1) and repeated this procedure again at eight
to 12 weeks (follow-up 2).
Control arm
TAU differs across sites; to ensure some standardisation
of practice in this trial, participants received their site’s
standard TAU. If this did not already include two con-
tacts within a 12-week period following medication initi-
ation, the sites were asked to add two contacts with the
consultant psychiatrist or paediatrician by the end of the
12-week study period. These contacts were either in per-
son or by telephone dependent upon the consultant’s
preference. This was designed to ensure both study arms
received a similar level of clinical contact during the
study period so that any differences between arms in
outcomes were more likely due to the addition of
QbTest rather than overall amount of clinical contact.
In both arms, the participant’s usual care team were
responsible for patient care and administering the
QbTests. Full details of the intervention and TAU have
been previously published in the protocol [14].
Fig. 1 CONSORT flow of participants. N = questionnaire with largest return at each time point. Asterisk indicates 1 participant withdrew after
completing baseline measures and intervention. 1 withdrew after completing all baseline measures except QbTest
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Randomisation and blinding
Participants were randomised on a 1:1 ratio into either
the QbTest medication arm (experimental arm) or con-
trol arm, using block randomisation stratified by site, via
sealed opaque envelopes. The clinicians or clinical re-
search staff were not blinded to allocation once random-
isation had occurred, but outcome assessors were blind
to arm allocation. Choice of medication did not have to
be selected prior to randomisation.
Measures
Feasibility and acceptability
Data were collected on a range of feasibility and accept-
ability measures. These included the number of partici-
pants randomised, number of people declining to take
part (along with reasons where given), withdrawals of
participants post-randomisation, number of outcome
measures completed by parents, children, and schools at
each time point, number of clinician pro formas (see
below) completed, number of QbTests conducted, and
participant and clinician opinions through interviews.
Between-group outcome measures
Parents and carers were given the choice of completing
outcome measures online, via telephone, or post. Clinicians
and teachers had the option of online or postal forms. All
participants and schools were included at each follow-up
regardless of previous missing data, unless they withdrew
from the study. When self-report questionnaires from
schools and families were not returned after two weeks,
they were re-sent and followed up via phone or email.
As this was a feasibility RCT, there was no specified
primary outcome. A full description of each measure
can be found in the protocol [19]. Details on the
validated data collection tools used to address the study
objectives can be found in the protocol [19], briefly the
measures were as follows:
Swanson, Noland and Pelham version IV (SNAP-IV)
[34]. A brief behavioural rating scale that measures core
symptoms ADHD and oppositional defiant disorder
(ODD), rated by parents and teachers
Strengths and Difficulties Questionnaire (SDQ) [35, 36].
A brief measure of behavioural and emotional difficulties
rated by parents and teacher
Child Health Utility 9 Dimensions (CHU9D) [37].
Completed by either the young person or parent to
provide a paediatric generic preference-based measure of
health-related quality of life
QbTest [18]. A 20-min computer test of attention and
impulsivity with a measure of activity, completed by the
young person
Clinical Global Impressions Scale (CGI) [38]. A brief
measure of overall severity and improvement in symp-
toms as rated by the clinician
Side effects scale [39]. A brief measure of common
anticipated side-effects in children with ADHD
Additional data collection tools were developed specific-
ally for the study, and a medication adherence question-
naire, a clinician pro forma, and study-specific health
economics questionnaires for participants and schools.
The medication adherence questionnaire is a short form
that allows the parent/carer to record the medication and
dose being taken by the child and how regularly it is taken.
The clinician pro forma records data on diagnoses and
clinical decision-making along with the resources used to
reach decisions. Two health economics questionnaires
were designed specifically for the study and examined the
inventory provided by Client Service Receipt Inventory
CSRI [40] but focusing on meaningful variables for
ADHD. One questionnaire titled ‘Resource Use – Services
for Education’ (RUSE) was designed to collect data on
education resources the child uses and was completed by
teachers. The other titled ‘Resource Use – Services for
Health’ (RUSH) was designed to be completed by parents/
carers to gather data relating to health services used by
families for the child, along with any impacts on family
life, such as time out of employment to care for the child.
In this study, we sought to assess the feasibility and ac-
ceptability of these new measures only; health economics
values are not reported. The time points when each meas-
ure was collected are shown in Table 2.
Qualitative interviews
All intervention and control participants, alongside a parent
or guardian, were invited to partake in telephone interviews
with a researcher (LW) to discuss their experience of
QbTest; clinicians were also invited to take part in a tele-
phone interview. Interview schedules for participants and
clinicians explored—from their different perspectives—the
experience of the study and the acceptability of QbTest for
its intended purpose. Schedules included questions aiming
to uncover barriers and facilitators relating to the protocol’s
implementation, engagement with the technology, and its
impact on care. Within the clinician interviews, normalisa-
tion process theory (NPT) [41] informed part of the sched-
ule in order to explore the potential future implementation
of QbTest. The domains of NPT are coherence (under-
standing around the purpose of QbTest), cognitive partici-
pation (engagement with the QbTest as part of care),
collective action (activities that people do to implement it),




Descriptive statistics (mean and standard deviation) were
summarised by group and across follow-up time (if
applicable) for each outcome measure. Preliminary
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treatment effects were examined using multi-level mod-
elling and are presented together with their 95% confi-
dence intervals. Recruitment rate, retention rate, and
completion rates of each measure were calculated from
the data. All statistical analysis was conducted using
STATA15.
Qualitative
The qualitative interviews were audio recorded, tran-
scribed verbatim, and analysed thematically following the
guidelines of Braun and Clarke [42]. Qualitative software,
NVivo 12, was used for coding and management of data.
Analysis was conducted using pre-defined areas of inquiry
relating to the primary research questions; researchers
focused on content in the following areas: acceptability of
the protocol (and whether any adjustments should be
made), desirability of QbTest as part of medication man-
agement, and for clinician interviews, the domains of NPT
were explored to provide early insight into its potential fu-
ture implementation. Throughout the process, researchers
were also attentive to data that was unexpected, which
was subsequently explored to decide whether it was of
interest to the aims of the study. Thus, the thematic
analysis was mainly driven by a particular set of aims, but




The first participant was enrolled on 18th December
2017 and recruitment ended on 30th October 2018. The
last participant exited the trial on 30th December 2018
when the trial ended.
In total, 54 participants were deemed eligible by
clinicians across the five sites and invited to participate
in the study. Demographics and clinical characteristics
of participants at baseline by randomised group are pre-
sented in Table 1. Randomisation was evenly split across
the study arms. Ten participants eligible for inclusion
declined to take part (see Fig. 1). Two participants with-
drew from the intervention arm after baseline assess-
ment (see Fig. 1).
Of five sites, one returned detailed information about
screening, eligibility, and recruitment. At this site, of 41
children identified as eligible, 11 were not approached
due to lack of clinic resources, eight families decided not
to start taking medication or the clinician decided not to
start medication then, eight did not want to take part in
the study, and four were initially interested but started
medication before a baseline test could be carried out.
This left a sample of 10 participants recruited at that
clinic over a 4-month period (25% recruitment rate).
Table 1 Participant demographics and clinical characteristics
Intervention (n = 21) Control (n = 23)
Mean (SD) age in years when entered the study 9.29 (2.81) 9.22 (2.19)
n (%) n (%)
Gender Male 20 (95.24) 19 (82.61)
Female 1 (4.76) 4 (17.93)
Ethnicity Bangladeshi 1 (4.76) 0
Dual heritage 1 (4.76) 0
Not given 1 (4.76) 0
Other 1 (4.76) 1 (4.35)
Pakistani 1 (4.76) 1 (4.35)
White 16 (76.19) 21 (91.30)
ADHD diagnosis ADHD combined subtype 18 (85.71) 14 (60.87)
ADHD—hyperactive-impulsive 2 (9.52) 5 (21.75)
ADHD—inattentive 1 (4.76) 2 (8.70)
Dual diagnosis ASD 0 1 (4.35)
Other clinical diagnoses ASD/social communication/speech difficulties 3 (14.28) 5 (21.75)
Attachment disorder 0 1 (4.35)
Conduct disorder 0 2 (8.70)
Tic and neurological disorders 2 (9.52) 0
Mood disorders 1 (4.76) 0
Data presented as n (%) unless otherwise specified. ADHD Attention deficit hyperactivity disorder, ASD Autism spectrum disorder
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Engagement with the intervention
Completion rates for questionnaire outcome measures
and QbTest decreased across the time points in each
arm, for each group (see Table 2).
Protocol deviations were noted in each arm. In the
intervention group, 37% (7/19) of follow-up 1 assess-
ments were completed within the 2–4-week timeframe
specified in the study protocol, and 53% (10/19)
completed follow-up 2 within the 12-week timeframe.
Information gained from the clinician completed pro
forma in the intervention arm found that across both
follow-ups, 73% (24/33 clinician responses) found
QbTest was useful in determining their treatment,
18% (6) were neutral, and 9% (3) stated it was not
Table 2 Measure completion rates at baseline, follow-up 1, and follow-up 2 for the intervention and control group
Outcome measure Intervention n (%) Control n (%)
Parents School Clinician Parents School Clinician
SNAP-IV
Baseline 10 (52) 12 (63) - 18 (78) 18 (78) -
Follow-up 1 11 (57) 15 (78) - 12 (52) 15 (65) -
Follow-up 2 10 (52) 9 (47) - 11 (47) 15 (65) -
SDQ
Baseline 13 (68) 12 (63) - 16 (69) 18 (78) -
Follow-up 2 9 (47) 9 (47) - 11 (47) 15 (65) -
CHU9D
Baseline 12 (63) - - 16 (67) - -
Follow-up 1 10 (52) - - 11 (47) - -
Follow-up 2 9 (47) - - 11 (47) - -
Medication Adherence Questionnaire
Follow-up 1 11 (57) - - 11 (47) - -
Follow-up 2 10 (52) - - 11 (47) - -
Side effects Questionnaire
Follow-up 1 11 (57) - - 11 (47) - -
Follow-up 2 10 (52) - - 11 (47) - -
RUSH
Follow-up 2 10 (52) - - 11 (47) - -
RUSE
Follow-up 2 - 9 (47) - - 13 (56) -
QbTest
Baseline 19 (100) - - 19 (82) - -
Follow-up 1 15 (78) - - - - -
Follow-up 2 11 (57) - - - - -
Clinician Proforma
Baseline - - 21 (100) - 22 (95)
Follow-up 1 - - 21 (100) - - 21 (91)
Follow-up 2 - - 18 (94) - - 20 (87)
CGI
Baseline - - 20 (95) - - 21 (91)
Follow-up 1 - - - - - -
Follow-up 2 - - 17 (81) - - 20 (87)
CGI Clinical global impression scale, completed by clinician at baseline and follow-up 2; CHU9D Child Health Utility 9D, completed by parents or child at baseline,
follow-up 1, and 2; SNAP-IV Swanson, Noland and Pelham IV Questionnaire, completed by parents and teachers at baseline, follow-up 1, and 2; SDQ Strengths and
Difficulties Questionnaire, completed by parents and teachers at baseline and follow-up 2; Medication adherence completed by parents at follow-up 1 and 2; Side
effects completed by parents at follow-up 1 and 2; RUSH Resource Use for Health, completed by parents at follow-up 2; RUSE Resource Use for Education,
completed by teachers at follow-up 2; QbTest Conducted at baseline for control group and at baseline, follow-up 1, and 2 for intervention group. Proforma
clinician proforma completed by clinicians at baseline, follow-up 1 and 2
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helpful. A further inspection revealed that more clini-
cians tended to find it helpful at follow-up 1 (76.5%,
13/17) than follow-up 2 (68.8%, 11/16).
In the control arm, the study protocol required two
contacts any time within the 12 week study period:
70% (16/23) of control participants had one contact
Table 3 Mean scores (SD) on outcome measures for the intervention and control groups
Completer Outcome measure Baseline Follow-up 1 Follow-up 2
Intervention Control Intervention Control Intervention Control
Parent SNAP-IV n = 10 n = 16 n = 11 n = 12 n = 10 n = 11
ODD 14.69 (4.96) 14.69 (6.69) 10.82 (6.75) 12.17 (7.30) 10.20 (6.01) 9.55 (5.66)
Hyp/Imp 19.46 (6.08) 20.75 (6.45) 14.64 (7.74) 17.92 (6.60) 12.80 (6.86) 15.33 (6.93)
Inattention 16.4 (5.14) 19.88 (4.30) 15.82 (5.74) 18.08 (5.58) 13.30 (5.36) 17.45 (5.54)
SDQ n = 13 n = 16 n = 10 n = 11
Emotional problems 4.08 (2.60) 4.50 (2.66) - - 4.00 (3.23) 4.52 (2.03)
Conduct problems 4.62 (2.57) 4.25 (2.14) - - 3.50 (2.22) 3.36 (1.57)
Hyperactivity 8.46 (2.37) 9.06 (1.06) - - 7.00 (2.67) 7.43 (1.80)
Peer problems 4.15 (2.30) 4.75 (2.11) - - 3.60 (1.78) 4.62 (2.86)
Prosocial 6.46 (2.37) 6.06 (1.98) - - 5.90 (2.42) 6.75 (1.49)
Total difficulties 21.31 (6.98) 22.56 (5.29) - - 18.10 (7.50) 19.92 (5.75)
Externalising 13.08 (4.54) 13.31 (2.70) - - 10.50 (4.55) 10.79 (3.20)
Internalising 8.23 (4.44) 9.25 (3.87) - - 7.60 (4.14) 9.13 (4.51)
Impact 4.62 (2.96) 5.27 (2.71) - - 3.78 (2.22) 3.94 (3.37)
Side effects scale n = 11 n = 10 n = 10 n = 11
- - 21.29 (11.31) 18.08 (9.84) 20.80 (14.34) 16.55 (10.87)
CHU9D n = 8 n = 8 n = 6 n = 7 n = 6 n = 7
24.75 (6.25) 22.88 (9.58) 20.83 (4.54) 19.92 (9.52) 21.83 (8.75) 15.57 (3.99)
Child CHU9D n = 5 n = 7 n = 9 n = 6 n = 3 n = 4
21.20 (7.69) 19.14 (5.67) 19.79 (5.33) 18.17 (5.04) 26.29 (13.69) 29.00 (2.16)
Teacher SNAP n = 13 n = 18 n = 8 n = 15 n = 9 n = 15
ODD 7.92 (6.44) 9.44 (6.87) 3.25 (2.12) 7.47 (4.47) 4.33 (4.56) 8.18 (5.72)
Hyp/Imp 10.62 (7.57) 14.72 (8.34) 4.75 (2.25) 12.67 (6.56) 4.44 (5.73) 11.93 (6.30)
Inattention 12.08 (7.37) 17.28 (7.54) 7.00 (5.13) 16.87 (6.21) 6.22 (5.31) 14.13 (5.57)
SDQ n = 11 n = 18 n = 9 n = 15
Emotional problems 3.00 (3.29) 3.39 (2.93) - - 1.56 (1.33) 3.20 (2.46)
Conduct problems 3.00 (2.93) 2.61 (2.17) - - 1.00 (1.12) 2.93 (2.43)
Hyperactivity-inattention 6.82 (2.68) 8.33 (1.91) - - 3.44 (2.19) 7.60 (2.32)
Peer problems 2.09 (1.81) 3.56 (2.04) - - 2.00 (1.50) 3.67 (2.13)
Prosocial 5.09 (2.66) 6.06 (2.48) - - 6.67 (2.35) 5.80 (2.21)
Total difficulties 14.91 (7.02) 17.89 (5.97) - - 8.00 (3.35) 17.40 (6.25)
Externalising 9.82 (5.40) 10.94 (3.08) - - 4.44 (3.09) 10.27 (4.25)
Internalising 5.09 (3.62) 6.94 (4.41) - - 3.56 (1.51) 6.87 (3.70)
Impact 2.09 (1.64) 3.22 (2.05) - - 0.75 (1.16) 1.67 (1.61)
Clinician CGI n = 20 n = 21 - - n = 17 n = 20
Severity 3.65 (0.98) 3.67 (1.32) - - 2.06 (1.14) 2.10 (1.23)
Improvement - - - - 1.82 (0.88) 2.37 (1.01)
Data are mean (1 SD). n sample size for analysis; CGI Clinical Global Impression, baseline and follow-up 2; CHU9D Child Health Utility 9D, baseline, follow-up 1, and
2; Hyp/Imp Hyperactivity/impulsivity; ODD Oppositional defiant disorder; SDQ Strengths and difficulties questionnaire, completed by parents and teachers at
baseline and follow-up 2; SNAP-IV Swanson, Noland and Pelham IV Questionnaire, completed by parents and teachers at baseline, follow-up 1, and 2
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Fig. 2 Modelled mean change (95% CI) on SNAP scores from baseline. Data shown are the mean and 95% confidence interval change from
baseline at each time point on the SNAP-IV in the control and intervention groups. a–d Parent and teacher ratings on the hyperactivity-
impulsivity and inattention subscales
Williams et al. Pilot and Feasibility Studies            (2021) 7:68 Page 10 of 18
with the clinical team within 12 weeks and 30% (7/23)
had two contacts within 12 weeks. No serious adverse
events were reported and the side effects scores de-
creased in both arms from T1 to T2.
Between-group outcome measures
All results from the between-group outcome mea-
sures are presented in Table 3 and changes in out-
come scores, along with 95% confidence intervals,
are provided in Table 4 for all measures except the
CHU9-D. Data analysis was not performed on the
CHU9D as initial checks on the data revealed it was
not meaningful to combine data from parent and
child respondents, resulting in sample sizes that
were too small for analysis. For all scales, higher
scores represent greater presence of symptoms/im-
pact. For the CGI, higher scores represent greater
improvement. Figure 2 shows the difference between
study arms over time on the SNAP-IV parent and
teacher scales and indicates greater improvement in
change scores in the intervention arm than the
control.
At follow-up 1, 55.6% (10/18) of cases in the experi-
mental arm underwent changes to their treatment plan
in comparison to only 33.3% (7/21) of cases in the
control arm. At follow-up 2, the figures were more com-
parable with slightly fewer changes planned in the inter-
vention arm (41.2%, 7/17) in comparison to the control
(47.4%, 9/19). In all instances, changes to the treatment
plan involved changes to the type or dose of ADHD
medication.
A comparison of medication adherence scores between
the two arms revealed similar results. For those that
responded, at follow-up 1, 100% (8/8) in the experimen-
tal arm and 88.8% (8/9) in the control arm reported tak-
ing their medication most/every day. At follow-up 2,
these figures were 87.5% (7/8) in the experimental arm
and 100% (9/9) in the control arm.
Qualitative data on acceptability of the protocol and of
QbTest as part of care
Eight participants agreed to be interviewed (six from the
intervention group and two from the control group). All
interviews were conducted with the children and young
people’s primary care- givers; whilst it was initially
intended that children would also be interviewed along-
side their parents, this proved difficult in the initial
interviews due to the young age of participants, and so
the focus shifted to interviewing parents only. The char-
acteristics of the children whose parents/primary care-
givers took part in an interview are presented in Table 5.
Five clinicians (from 4 of the 5 clinic sites) agreed to be
interviewed, four of which were community paediatri-
cians and one was a psychiatrist; all were female.
The interviews showed a range of challenges and bene-
fits of using the QbTest as part of medication manage-
ment. Attention was paid to what aspects of the
protocol might require amendment and which aspects
were acceptable, in order to inform any subsequent trial
design for a full RCT. The themes presented show the
acceptability of taking part in the trial and highlights
how the test fitted (or did not fit) within everyday care.
Theme 1: Acceptability of being part of a study
Separate to having QbTest form part of a person’s care,
it is also important to understand the acceptability of
trial procedures to families and children. This includes
core elements such as randomisation and completion of
multiple questionnaires. It was therefore crucial to
understand how this was experienced by families.
Randomisation and recruitment None of the partici-
pant interviews indicated concerns with randomisation
and all understood they may be allocated to either study
arm. Those in the intervention arm were pleased to have
been randomised into that group and discussed perceived
benefits of being randomised into the QbTest arm, not-
ably, the opportunity to have additional QbTests.
Table 5 Characteristics of child participants whose parents/carers were interviewed
ID Age of child (years) ADHD diagnosis Any other diagnosis Site Study arm
P1 6 ADHD combined subtype No 1 Intervention
P2 11 ADHD combined subtype No 3 Intervention
P3 12 ADHD combined subtype No 1 Intervention
P4 6 ADHD combined subtype Yes 1 Intervention
P5 9 ADHD combined subtype Yes 4 Intervention
P6 9 ADHD combined subtype No 4 Intervention
P7 8 ADHD combined subtype Yes 1 Control
P8 9 ADHD predominantly inattentive No 2 Control
ADHD Attention deficit hyperactivity disorder
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Yeah I was fine! It’s like, sort of like, 50/50, so does
it make any difference!—P8
It didn’t bother me at all really. Because I mean
obviously, we’ve had that additional care there
with him having the three QbTests, which, as I
say has been helpful for us when we noticed
there was a change in his behaviour. So, you
know, I was quite happy that we were put into
that category.—P1
Those in the control group also felt that their
telephone consultations were helpful and indicated that
there was some benefit from being in the TAU arm
because this required less effort than the three QbTests
in the intervention arm.
Yeah, yeah, it worked really well, because it was
much easier than having to try and lug him there,
and obviously it didn’t disrupt his routine or
anything like that as well.—P7
Completing questionnaires Parents had no reservations
about completing questionnaires and found them useful
in highlighting areas of improvement or change, albeit
noting there were multiple questionnaires.
Yeah, as I say, we noticed improvements, the forms
are obviously standardised and repetitive, but yeah
you can sort of see, you know, you’re making the
change obviously as you’re noticing the behavioural
change. So yeah, they were absolutely fine.—P1
Theme 2: QBTest as part of care
Factoring in multiple appointments Having QbTest as
part of care meant that additional appointments were
required in order to conduct tests and review results.
This could provide both a challenge (in terms of add-
itional burden) and also benefit (in terms of add-
itional care for families, and quicker medication
titration). The impact on both clinicians and families
will be considered.
Scheduling three appointments within 12 weeks posed
some logistical challenges for clinicians and services.
The protocol required them to schedule appointments
within shorter timeframes than demand on the clinics
would ordinarily allow. Other considerations surrounded
the use of clinic time in close succession when they
might not have considered it necessary to have an
appointment to monitor the medication so soon after
the last appointment.
For one, our clinic time is very precious so we don’t
have the luxury of seeing families so close, erm,
together in appointments, and also I am not sure if
that is clinically required.—C3
In contrast, the primary care-givers valued the short
time frame and described it as beneficial to them and
their families.
I think it has been good to have that support.
Because, when we have been in the past, we have
had an appointment and then not been seen for
months and months. P3
The primary care-givers in this sample were satisfied
with the study’s appointment schedule, but they had
wider concerns regarding the time out of school that
clinical appointments and QbTests required, which were
not limited to the study, but also related to their overall
ADHD care pathway. Whilst it was discussed that ap-
pointments before school, after school, and in school
holidays would be preferable to missing school, ultimately
attending the appointments was considered beneficial.
I would have been fine, because it was for my child’s
welfare, and so, you know, I would be quite happy
to go to the appointment. But these appointments
are all set out for before school or during school, so
it is always missing education time, … so I wish they
made, you know, appointments in June half term, or
after-school appointments, or something like that. It
would be helpful.—P5
The clinicians also noted that clinic appointments
often occur during working hours which has implica-
tions for children and young people missing school and
also requires primary care-givers to take time out of
work. Running multiple QbTest appointments could in-
crease these problems.
Do children want to come in on a Saturday morning?
Probably not! But parents, parents might find it quite
useful because they are not necessarily having to take
time off work.—C5
Avoiding unnecessary workload Whilst the implemen-
tation of QbTest undoubtedly meant conducting
additional tests, clinicians voiced a preference to do this
only when it was perceived to add value. Clinicians
raised concerns about the requirement to conduct
QbTests on all of the intervention participants. They
described QbTest as one of a suite of tools they use to
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monitor ADHD symptoms and felt that the additional
resources required to carry out QbTests (staffing, clinic
time, and test interpretation) are not necessary in rou-
tine cases but may be of use in trickier cases. Some also
considered repeat QbTests to be burdensome for the
children and young people.
… I wouldn’t think it is a great use of resources for
every child with ADHD to have it in order to
monitor their medication. I think it would be more
helpful for the more complicated children who had,
you know, other things going on as well, and where
the situation wasn’t entirely clear.—C4
The second follow up in the experimental arm was
too much, especially for the children. A lot of the
children did not want to do the QbTest, or they
have one for the assessment, one for the follow up
and one for the second, and, you know, some
children are compliant and will just do as they are
asked to do, but some really didn’t and said ‘I don’t
want to do it.—C3
An additional point raised by clinicians was that a
greater number of participants could have been eligible
to take part in the study if the time window of the base-
line QbTest was increased. The study protocol stipulated
that a QbTest conducted within 12 weeks prior to inclu-
sion in the study could be used as the baseline QbTest.
Any QbTest conducted prior to this previous 12 weeks
was considered unreliable, due to potential changes in
symptoms, and a new QbTest was required. Clinicians
felt that this time window could be increased to widen
eligibility and that this would be more in keeping with
their clinical practice, where patients with a QbTest
older than 12 weeks would not be requested to repeat
the test before medication was prescribed.
Theme 3: Confidence and communication
QbTest was described by both groups (parents and clini-
cians) as increasing their confidence in the child’s treat-
ment. Whilst clinicians did not perceive it as necessary
in all cases, they found it particularly helpful in more
complex cases (as described above).
Primary care-givers considered the repeated QbTests
to be useful in increasing confidence in ongoing medica-
tion decisions as well as a tool the clinicians used to
communicate changes in ADHD symptoms. They did
not view the QbTests as burdensome to the children
and young people, but they were considered ‘boring’ by
some of the children who undertook them.
Yes, because I brought them home and showed my
partner as well, and I have been able to explain to
him what they mean and he can understand it as
well, and we have been able to see the difference on
that. It might just be a scribble on a piece of paper,
but we can see that there is a difference.—P3
He can have as many of them as they want to give
him, it don’t hurt him so, it’s only 15 minutes of his
life it’s not going to kill him.—P2
Both groups voiced the potential of QbTest as an aid
to communication. Parents described above how a visual
representation of their child’s symptoms helped them to
better understand the impact of treatment. For clini-
cians, similar views were expressed, and they also de-
scribe it as giving extra weight to their advice during
consultations. Therefore, whilst the QbTest is both an
aid to communication, it is also a powerful additional
‘voice’ in the discussion. This appears to help parents be
more accepting of treatment recommendations.
There are times when families say it [medication]
doesn’t work because they are focusing on the
behavioural problems which I do not expect the
medication to make a huge impact on…so I use the
QbTest as a way to talk to them and say ‘look
changing the medication or increasing the medication
is not going to make a huge difference to the
behaviour which we need to address in a different
way, so the QbTest is often quite helpful to have
those sort of conversations.—C3
Discussion
The aim of this study was to assess the feasibility and
acceptability of adding QbTest to treatment as usual to
monitor medication outcomes in ADHD after initiation
of stimulant medication [19, 31]. The study protocol was
tested in a feasibility RCT and primary care-givers and
clinicians involved in the study were interviewed. The
findings indicate that the protocol was generally consid-
ered acceptable to primary care-givers and clinicians but
that some changes are required to improve participant
recruitment rates and the feasibility of implementing the
protocol within clinical services. These issues were dis-
cussed at a stakeholder workshop held immediately after
the end of participant recruitment, attended by 16 stake-
holders, including representation from each clinic site,
the core research team, and PPI members [31]. The aim
of the workshop was to identify potential barriers to
implementing the protocol and possible ways to refine
the protocol to overcome these barriers in a future trial.
We now discuss the main findings from the study and
will make reference to the comments made by stake-
holders at this workshop, throughout.
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Feasibility and acceptability of recruitment and
randomisation
Recruitment of participants was more difficult than
anticipated and the final sample size of 44 was below the
target sample size of 60. During interviews, it became
clear that the recruitment difficulties were more strongly
related to the feasibility of implementing the study
protocol within clinical services than the acceptability of
the protocol to potential participants. Only one potential
participant declined to take part due to randomisation
and three declined to take part because they felt comple-
tion of the outcome measures would be too burden-
some. None of the parent/carers who were interviewed
considered randomisation to be negative and, when
further questioned, understood they may be allocated to
either study arm and were comfortable with this.
Conversely, whilst clinicians commented positively on
the QbTest in interviews, they highlighted some issues
with the feasibility of the protocol. Specifically, the
clinicians felt that the requirement that a baseline
QbTest must have been completed within 12 weeks prior
to medication initiation limited the numbers of eligible
participants. This requirement also did not fit with usual
practice where QbTest results older than 12 weeks are
often used as a baseline prior to medication initiation.
The clinicians felt that this inadvertently excluded
families who were returning to the pathway after taking
some time to make a decision about whether to com-
mence medication. Although in the current protocol
participants could complete a new baseline QbTest at
the point of medication initiation, the reality of schedul-
ing this test would have meant a delay in starting medi-
cation, which would have been unethical. In the future,
expanding the timeframe for existing QbTests would in-
crease the number of families eligible to be approached
to take part in the study.
Outcome measures
The completion and return of study outcome measures
by primary care-givers and teachers was similar across
measures, although returns by teachers were affected by
the timing of school holidays, particularly the long (6-
week) summer holidays. Our response rates were lower
than we would anticipate based on similar trials [27];
however, during interviews, the primary care-givers
acknowledged that although the trial included several
questionnaires, they were not unduly burdened by com-
pleting them. Based on our previous experience of
successful trials, we would implement the following
strategies to facilitate completion rates: conduct mea-
sures online with researcher telephone support where
needed, including out-of-hours telephone appointments,
and provide personalised thank you messages when
measures are complete. The completion of study mea-
sures by clinicians was also high but, during interviews,
clinicians commented that the clinician pro forma (de-
veloped specifically to enable clinicians to record clinical
decision-making within this study) needs to be refined
to more reflective of clinician practice and decision-
making.
One aim of this study was to identify a primary out-
come measure for a future RCT. The SNAP-IV mean
scores and change in mean scores, as well as difference
in this change between arms, suggests this would be a
useful primary outcome to measure the clinical utility of
adding QbTest to medication management for ADHD.
Furthermore, the return rate for this measure was
comparable with the other measures, even though the
requirement was for parents and teachers to complete it
at all time points. Additionally, parents and clinicians in
our previous workshops identified changes on the
SNAP-IV as being the most meaningful outcome [43]
Health economics questionnaires, RUSH and RUSE,
were designed specifically for the study, and examined
the inventory provided by CSRI [40] but focusing on
meaningful variables for ADHD. The measures were co-
designed by an expert in health economics (MJ), experts
in ADHD (MG, KS, CH) and PPI representatives. Pri-
mary care-givers and teachers were asked to complete
the measures at the second follow-up. The return rates
were similar to the other measures, but some items were
unanswered, suggesting that respondents either did not
know how to answer some questions or felt they were
not relevant. Amendments to these measures will be
required before they can be used to assess service use in
a full RCT. In addition, the CHU9D, a measure of child
health utility that is used in combination with life-years
to calculate quality-adjusted life-years (QALYs), can be
completed by either the child or primary care-giver.
Repeated measures are crucial to establish a change in
health over time, but there is a requirement that the
same respondent completes the measure at each time
point. In this study, a mixture of parents and children
completed the measure at different time points, render-
ing the data unsuitable for analysis. To enhance the
feasibility of this measure in a future trial, a prior deci-
sion should be made as to whether the parent/carer or
child should complete the measure, and this should be
communicated clearly to families.
Although medication adherence was comparable
across both groups, it is noteworthy that our sample was
young (mean age 9 years), whereas research shows that
evidence of medication effectiveness is important to
increase adherence in older teenage children [44], a
further trial including older children would be needed to
fully assess this. It is also noteworthy that medication
adherence was relatively high in general, which may be
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because the follow-up period was short (maximum 10–
12 weeks).
Participants were given a choice between completing
their outcome measures via post, online, or over the
phone. The majority requested post but, when ques-
tioned, stated that they would have been willing to
complete questionnaires online. This would be a more
cost-effective and pragmatic approach in the future with
the option of postal returns reserved only for families
with no internet access. In addition, participants in the
intervention arm could be given the option of complet-
ing outcome measures at their follow-up appointments
to increase completion rates.
Engagement with intervention and protocol adherence
Engagement with the intervention was high amongst
participants. Only two participants withdrew from the
intervention group at baseline and only one of the
remaining participants did not attend their clinic ap-
pointments. Interview data reflected positive engagement
from the families. Although during interviews the
clinicians raised concerns about the burden of multiple
QbTests for the children and young people, parents
raised no concerns about attending three QbTests in 12
weeks and did not seem to feel that this was burden-
some to the child. However, the requirement for the
child to take time out of school to attend healthcare
appointments was viewed negatively by parents and
care-givers. These comments were not specific to the ap-
pointments required by the study protocol but reflective
of more general disruptions to schooling that arise from
the ADHD assessment and diagnosis ‘journey’.
The clinics recorded a large number of protocol devia-
tions in terms of completion of follow-ups within the
study protocol timeframe. Only 37% of QbTests in the
intervention arm were completed within 2–4 weeks of
medication initiation and only 30% of two follow-up
contacts in the control arm were completed within the
12-week study timeline. Interviews with the clinicians re-
flect that the appointment schedules for both arms were
challenging for the clinics. The first follow-up was diffi-
cult for clinics to adhere to because appointment sched-
ules are often filled at least 4 weeks in advance, leaving
very little flexibility for clinicians to schedule the study
appointments. Clinicians reported holding some ap-
pointments outside their usual clinic times to deal with
this problem, but this would not be feasible in a larger
trial. One option would be to design a more flexible trial
protocol that can be adapted to fit with each service’s
appointments system.
Interestingly, findings from the pro forma indicated
that early use of the QbTest on medication may be most
beneficial, with clinicians making more treatment
changes (changing dose or type of ADHD medication)
in the experimental arm at follow-up 1 compared to the
control group, but little difference at follow-up 2. This
may be because the QbTest promoted earlier treatment
optimisation, which was also evidenced in the improved
SNAP-IV scores and more clinicians reporting the
clinical utility of QbTest at follow-up 1 than 2. We are
cautious not to over-interpret findings from this small
sample; however, this warrants further investigation and
suggests that a more naturalistic protocol allowing clini-
cians to use QbTest according to their clinical judgment
(but with a minimum of one pre and post medication
test) may be more suitable.
QbTest and clinic management
Interview data indicated that the objectivity of the
QbTest was appreciated by clinicians and parents alike
in comparison to informant measures that are tradition-
ally used to monitor medication. Clinicians also
commented that it is not feasible to use QbTest in medi-
cation management for all cases due to the additional
clinic time and resources required, when balanced
against the additional information that Qb gives; for
more simple cases, it is sufficient to monitor medication
using established clinical methods. However, there is
perceived value in using QbTest for more complex pa-
tients, which includes co-morbidities, and any examples
where there is contention about treatment approaches,
for which case Qb is particularly helpful. The interview
data also indicated that clinicians find QbTest helpful in
communication with families, including reaching a
shared decision about any particular course of action.
These findings relate to normalisation process theory in
two ways. Firstly, that normal working practices do not
fit with the use of QbTest in every case, due to the add-
itional workload it brings and secondly, alongside this,
clinicians do not consider it necessary to use QbTest for
every case, but prefer to reserve it for complex cases.
These findings have implications for the design of a full
RCT and any expectation of the implementation of the
intervention post-trial.
Strengths and limitations
This study is strengthened by the involvement of
multiple stakeholders, including PPI and clinicians
[31]. These stakeholders were instrumental in de-
signing the protocol in the first stage of the study
and in evaluating the feasibility and acceptability of
the protocol once data collection ended, including
via the post-study workshop described above. These
insights have led to the following refinements to the
protocol to improve its feasibility and acceptability
in a definitive RCT. Firstly, difficulties with recruit-
ment led to a sample size smaller than the target of
60. As identified by stakeholders, extending the time
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period over which a prior QbTest can be considered
a baseline for medication is likely to mitigate these
difficulties to some extent. Secondly, the pool of eli-
gible participants is relatively small and so it is likely
that a larger trial at a greater number of sites would
reduce these recruitment difficulties. Thirdly, a more
flexible protocol with a larger timescale for follow-
up assessments, also identified by our stakeholders,
will enhance feasibility of data collection by enabling
clinicians to use QbTest in a more flexible manner
and by allowing longer for follow-up assessments to
be completed. Fourthly, although not the purpose of
a feasibility trial, a definitive efficacy trial should
record whether the time of day of follow-up QbTest
influenced treatment decision-making plans as test
interpretation may differ according to whether the
effect of stimulant medication has worn off. A final
point to consider is that our qualitative interviews
were only conducted with parents as children were
unwilling to participate or deemed too young by
their parents. Although this is common with this
young sample [26], we will work with key stake-
holders to refine our methods for gathering insight
into the experiences of young people.
Conclusion
The findings of this study suggest that, with some modifi-
cations to the follow-up time periods, the method of data
collection, and refinement in the methods for health eco-
nomics data collection, the protocol may be appropriate
for a full clinical trial. The stakeholders judged that with
further modifications as described, the protocol would be
more feasible to implement and would be clinically benefi-
cial. The findings further suggest that the SNAP-IV would
be a useful primary outcome for reflecting change in
symptoms between trial arms.
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